Published in Biochem Soc Trans on February 01, 1990
Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother (1995) 7.44
Amino acid substitutions in the cytochrome P-450 lanosterol 14alpha-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob Agents Chemother (1998) 4.93
Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother (2001) 4.05
Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro. Antimicrob Agents Chemother (1997) 3.78
Fluconazole-resistant recurrent oral candidiasis in human immunodeficiency virus-positive patients: persistence of Candida albicans strains with the same genotype. J Clin Microbiol (1994) 3.64
Characterization of an azole-resistant Candida glabrata isolate. Antimicrob Agents Chemother (1992) 3.23
Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrob Agents Chemother (1996) 3.03
Distinct patterns of gene expression associated with development of fluconazole resistance in serial candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob Agents Chemother (1998) 2.93
Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia. Antimicrob Agents Chemother (1997) 2.43
Molecular biological characterization of an azole-resistant Candida glabrata isolate. Antimicrob Agents Chemother (1997) 2.27
Sterol 14alpha-demethylase cytochrome P450 (CYP51), a P450 in all biological kingdoms. Biochim Biophys Acta (2006) 2.09
Correlation between rhodamine 123 accumulation and azole sensitivity in Candida species: possible role for drug efflux in drug resistance. Antimicrob Agents Chemother (1996) 1.89
Fluconazole resistance associated with drug efflux and increased transcription of a drug transporter gene, PDH1, in Candida glabrata. Antimicrob Agents Chemother (1998) 1.76
Specific chromosome alterations in fluconazole-resistant mutants of Candida albicans. J Bacteriol (1999) 1.73
Candida glabrata PDR1, a transcriptional regulator of a pleiotropic drug resistance network, mediates azole resistance in clinical isolates and petite mutants. Antimicrob Agents Chemother (2006) 1.70
Functional genomic analysis of fluconazole susceptibility in the pathogenic yeast Candida glabrata: roles of calcium signaling and mitochondria. Antimicrob Agents Chemother (2004) 1.46
Fluconazole- and itraconazole-resistant Candida albicans strains from AIDS patients: multilocus enzyme electrophoresis analysis and antifungal susceptibilities. J Clin Microbiol (1995) 1.44
Antifungal resistance and new strategies to control fungal infections. Int J Microbiol (2011) 1.44
Multiple resistant phenotypes of Candida albicans coexist during episodes of oropharyngeal candidiasis in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother (1999) 1.43
In vitro and in vivo effects of 14alpha-demethylase (ERG11) depletion in Candida glabrata. Antimicrob Agents Chemother (2001) 1.13
Genetic analysis of azole resistance in the Darlington strain of Candida albicans. Antimicrob Agents Chemother (2000) 1.09
Relationships between respiration and susceptibility to azole antifungals in Candida glabrata. Antimicrob Agents Chemother (2003) 1.06
Fluconazole treatment is effective against a Candida albicans erg3/erg3 mutant in vivo despite in vitro resistance. Antimicrob Agents Chemother (2006) 0.98
In vitro activity of a new antifungal triazole, D0870, against Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus. Antimicrob Agents Chemother (1994) 0.95
Amino acid substitutions at the major insertion loop of Candida albicans sterol 14alpha-demethylase are involved in fluconazole resistance. PLoS One (2011) 0.81
Transcriptional profile of Paracoccidioides spp. in response to itraconazole. BMC Genomics (2014) 0.78
Gene Expression and Identification Related to Fluconazole Resistance of Candida glabrata Strains. Osong Public Health Res Perspect (2010) 0.76
Tetramisole (R 8299), a new, potent broad spectrum anthelmintic. Nature (1966) 30.39
Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J Mol Biol (1994) 3.85
Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors. Life Sci (1981) 3.71
Molecular mechanisms of drug resistance in fungi. Trends Microbiol (1994) 3.55
The effects of methyl (5-(2-thienylcarbonyl)-1H-benzimidazol-2-yl) carbamate, (R 17934; NSC 238159), a new synthetic antitumoral drug interfering with microtubules, on mammalian cells cultured in vitro. Cancer Res (1976) 3.52
Vascular effects of ketanserin (R 41 468), a novel antagonist of 5-HT2 serotonergic receptors. J Pharmacol Exp Ther (1981) 3.47
Characterization of an azole-resistant Candida glabrata isolate. Antimicrob Agents Chemother (1992) 3.23
Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology (1999) 3.19
An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo-[4,5,1-jk] [1,4]benzodiazepin-2 (1H)-one and -thione derivatives. Proc Natl Acad Sci U S A (1991) 2.37
Mechanisms and clinical impact of antifungal drug resistance. J Med Vet Mycol (1994) 2.32
The preparation and antimycotic properties of derivatives of 1-phenethylimidazole. J Med Chem (1969) 2.28
Ketoconazole -- a new broad spectrum orally active antimycotic. Experientia (1979) 2.24
Two groups of rhinoviruses revealed by a panel of antiviral compounds present sequence divergence and differential pathogenicity. J Virol (1990) 2.19
Inhibition and induction of microsomal enzymes in rat. A comparative study of four antimycotics: miconazole, econazole, clotrimazole and ketoconazole. Arch Int Pharmacodyn Ther (1981) 2.00
Hypothesis on the molecular basis of the antifungal activity of N-substituted imidazoles and triazoles. Biochem Soc Trans (1983) 1.85
Itraconazole, a new triazole that is orally active in aspergillosis. Antimicrob Agents Chemother (1984) 1.83
Delay of castor oil diarrhoea in rats: a new way to evaluate inhibitors of prostaglandin biosynthesis. J Pharm Pharmacol (1978) 1.76
Anti-Candida drugs--the biochemical basis for their activity. Crit Rev Microbiol (1987) 1.76
Effects of itraconazole on cytochrome P-450-dependent sterol 14 alpha-demethylation and reduction of 3-ketosteroids in Cryptococcus neoformans. Antimicrob Agents Chemother (1993) 1.72
Photochemical stroke model: flunarizine prevents sensorimotor deficits after neocortical infarcts in rats. Stroke (1989) 1.70
Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant. J Mol Biol (1996) 1.65
Loperamide (R 18 553), a novel type of antidiarrheal agent. Part 1: in vivo oral pharmacology and acute toxicity. Comparison with morphine, codeine, diphenoxylate and difenoxine. Arzneimittelforschung (1974) 1.65
Activity of orally, topically, and parenterally administered itraconazole in the treatment of superficial and deep mycoses: animal models. Rev Infect Dis (1987) 1.64
Rhodamine 6G efflux for the detection of CDR1-overexpressing azole-resistant Candida albicans strains. J Antimicrob Chemother (1999) 1.54
Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors. Nat Struct Biol (1995) 1.53
Licensed midwife-attended, out-of-hospital births in Washington state: are they safe? Birth (1994) 1.52
The antiinflammatory effects of ketoconazole. A comparative study with hydrocortisone acetate in a model using living and killed Staphylococcus aureus on the skin of guinea-pigs. J Am Acad Dermatol (1991) 1.52
A TIBO derivative, R82913, is a potent inhibitor of HIV-1 reverse transcriptase with heteropolymer templates. Antiviral Res (1991) 1.51
Loperamide (R 18 553), a novel type of antidiarrheal agent. Part 3: in vitro studies on the peristaltic reflex and other experiments on isolated tissues. Arzneimittelforschung (1974) 1.51
In vitro activity of R 61837, a new antirhinovirus compound. Arch Virol (1988) 1.49
Use of a pedicled omental flap in the treatment of an infected vascular prosthetic graft. Eur J Vasc Endovasc Surg (1995) 1.45
Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues. Bioorg Med Chem Lett (2001) 1.44
P450 inhibitors of use in medical treatment: focus on mechanisms of action. Pharmacol Ther (1995) 1.43
In vitro activity of pirodavir (R 77975), a substituted phenoxy-pyridazinamine with broad-spectrum antipicornaviral activity. Antimicrob Agents Chemother (1992) 1.42
Safety and efficacy of intranasal pirodavir (R77975) in experimental rhinovirus infection. Antimicrob Agents Chemother (1992) 1.41
Biochemical approaches to selective antifungal activity. Focus on azole antifungals. Mycoses (1989) 1.38
The absolute configurations of the optical isomers of the broad spectrum anthelmintic tetramisole. Tetrahedron Lett (1967) 1.36
Suppression of colds in human volunteers challenged with rhinovirus by a new synthetic drug (R61837). Antimicrob Agents Chemother (1989) 1.33
Is it possible to predict the clinical effects of neuroleptic drugs (major tranquillizers) from animal data? IV. An improved experimental design for measuring the inhibitory effects of neuroleptic drugs on amphetamine-or apomorphine-induced "Cheroing" and "agitation" in rats. Arzneimittelforschung (1967) 1.33
Synergic effects of tactolimus and azole antifungal agents against azole-resistant Candida albican strains. J Antimicrob Chemother (1998) 1.32
Hepatic reactions during ketoconazole treatment. Am J Med (1983) 1.32
Identifying women at-risk for postpartum depression in the immediate postpartum period. Acta Psychiatr Scand (2004) 1.30
Loperamide (R 18 553), a novel type of antidiarrheal agent. Part 2: in vivo parenteral pharmacology and acute toxicity in mice. Comparison with morphine, codeine and diphenoxylate. Arzneimittelforschung (1974) 1.30
Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther (1988) 1.29
The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance. J Mol Biol (2001) 1.29
Interaction between 5-hydroxytryptamine and other vasoconstrictor substances in the isolated femoral artery of the rabbit; effect of ketanserin (R 41 468). Eur J Pharmacol (1982) 1.29
Domperidone, a novel and safe gastrokinetic anti-nauseant for the treatment of dyspepsia and vomiting. Arzneimittelforschung (1978) 1.28
Motor-stimulating properties of cisapride on isolated gastrointestinal preparations of the guinea pig. J Pharmacol Exp Ther (1985) 1.26
Etomidate, R-(+)-ethyl-1-( -methyl-benzyl)imidazole-5-carboxylate (R 16659), a potent, short-acting and relatively atoxic intravenous hypnotic agent in rats. Arzneimittelforschung (1971) 1.24
The biochemical mechanism of action of the antinematodal drug tetramisole. Biochem Pharmacol (1969) 1.24
Origin of differences in susceptibility of Candida krusei to azole antifungal agents. Mycoses (1995) 1.23
Hypothesis on the mechanism of resistance to fluconazole in Histoplasma capsulatum. Antimicrob Agents Chemother (1997) 1.23
Prediction of binding affinities for TIBO inhibitors of HIV-1 reverse transcriptase using Monte Carlo simulations in a linear response method. J Med Chem (1998) 1.20
New antihistaminic N-heterocyclic 4-piperidinamines. 3. Synthesis and antihistaminic activity of N-(4-piperidinyl)-3H-imidazo[4,5-b]pyridin-2-amines. J Med Chem (1985) 1.20
Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta 1-adrenergic antagonist. J Cardiovasc Pharmacol (1988) 1.18
Intranasal pirodavir (R77,975) treatment of rhinovirus colds. Antimicrob Agents Chemother (1995) 1.18
Pimozide, a chemically novel, highly potent and orally long-acting neuroleptic drug. I. The comparative pharmacology of pimozide, haloperidol, and chlorpromazine. Arzneimittelforschung (1968) 1.16
Benzetimide and its optical isomers. Arzneimittelforschung (1971) 1.15
Mechanisms of action of loperamide. Scand J Gastroenterol Suppl (1984) 1.15
Effect of cinnarizine on peripheral circulation in dogs. Eur J Pharmacol (1972) 1.11
Pimozide, a chemically novel, highly potent and orally long-acting neuroleptic drug. 3. Regional distribution of pimozide and of haloperidol in the dog brain. Arzneimittelforschung (1968) 1.11
Mode of action studies. Basis for the search of new antifungal drugs. Ann N Y Acad Sci (1988) 1.10
The biochemical mechanism of action of the anthelmintic drug tetramisole. Life Sci (1967) 1.08
In vivo pharmacology of astemizole, a new type of H1-antihistaminic compound. Arch Int Pharmacodyn Ther (1981) 1.08
Evidence that phospholipid turnover is the signal transducing system coupled to serotonin-S2 receptor sites. J Biol Chem (1985) 1.08
Comparative study of the effects of flunarizine and cinnarizine on smooth muscles and cardiac tissues. Arch Int Pharmacodyn Ther (1973) 1.06
The interaction of miconazole and ketoconazole with lipids. Biochem Pharmacol (1982) 1.06
Pharmacokinetics of R 82913 in patients with AIDS or AIDS-related complex. Lancet (1991) 1.05
Inhibition of 5-hydroxytryptamine-induced and -amplified human platelet aggregation by ketanserin (R 41 468), a selective 5-HT2-receptor antagonist. Agents Actions (1982) 1.04
Biochemical basis for the activity and selectivity of oral antifungal drugs. Br J Clin Pract Suppl (1990) 1.03
The receptor binding profile of the new antihypertensive agent nebivolol and its stereoisomers compared with various beta-adrenergic blockers. Mol Pharmacol (1988) 1.03
Results of a 10 week community based strength and balance training programme to reduce fall risk factors: a randomised controlled trial in 65-75 year old women with osteoporosis. Br J Sports Med (2001) 1.02
Does endothelin-1 mediate endothelium-dependent contractions during anoxia? J Cardiovasc Pharmacol (1989) 1.02
Experimental systemic dermatophytosis. J Invest Dermatol (1984) 1.01
The antiemetic effects of domperidone, a novel potent gastrokinetic. Arch Int Pharmacodyn Ther (1980) 1.01
Factors regulating drug cue sensitivity: the effect of training dose in fentanyl-saline discrimination. Neuropharmacology (1980) 1.00
Ibuprofen versus acetaminophen with codeine for the relief of perineal pain after childbirth: a randomized controlled trial. CMAJ (2001) 1.00
The peripheral and central anticholinergic properties of benzetimide (R 4929) and other atropine-like drugs as measured in a new anti-pilocarpine test in rats. Psychopharmacologia (1967) 0.99
Saperconazole: a selective inhibitor of the cytochrome P-450-dependent ergosterol synthesis in Candida albicans, Aspergillus fumigatus and Trichophyton mentagrophytes. Mycoses (1991) 0.99
Culture media for the study of the effects of azole derivatives on germ tube formation and hyphal growth of C. albicans. Mykosen (1986) 0.98
The antipyretic effect of suprofen in rats with yeast-induced fever. Arzneimittelforschung (1975) 0.97
Accumulation of 3-ketosteroids induced by itraconazole in azole-resistant clinical Candida albicans isolates. Antimicrob Agents Chemother (1999) 0.97